000919.SZ
金陵药业
SZSE · Healthcare · C 制造业 · CN
CNY 6.51
−1.96%Year over year
Reported trailing growth
- Revenue
- -2.8%
- EBITDA
- —
- EBIT
- +1101.4%
- EPS
- +213.1%
- Free cash flow
- +375.6%
- Operating cash flow
- +29.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +6.2%
- EBITDA
- -2.7%
- EBIT
- -18.9%
- Net income
- -20.0%
- EPS
- -25.4%
- Free cash flow
- +134.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026